Mitochondrial redox protein quality control in ageing

Lead Research Organisation: University of Glasgow
Department Name: College of Medical, Veterinary, Life Sci

Abstract

Mitochondria are fundamental components of animal cells that are essential for proper cell metabolism and physiology. To work properly mitochondria need to respond to stress and metabolic changes, adapt their protein content accordingly and adjust their function across the lifespan of an organism. Our project will address exactly these questions using simple yeast cells and fly models. Mitochondrial dysfunction is linked to ageing, and to numerous human pathologies and so the maintenance of their normal function is very important. Mitochondria produce small molecules called reactive oxygen species (ROS) which are important for signalling in the cell but at high levels become highly damaging. On the other hand, protein maintenance in mitochondria is subject to redox control but the details of this process are still elusive. In our project we will elucidate how a redox-dependent mechanism allows proper quality control of the proteins in mitochondria and how this in turns allows cell survival and proper development across the lifespan of an organism, particularly in the face of deleterious stresses. This is absolutely critical because maintaining a fine balance between redox proteins and ROS species makes all the difference for ROS being beneficial as signalling molecules in low levels or reverting to damaging agents for the cell at high levels.
We will first investigate the function of a reductive machinery that we recently found to be targeted to the intermembrane space (IMS) between the outer and inner mitochondrial membranes. This could impact on either ensuring correct folding of proteins in the IMS or efficient clearance in case where they are misfolded. Then, we will ascertain how the redox machinery in the IMS provides a surveillance mechanism to maintain a balanced redox state not just for proteins but also for small metabolite molecules that are made in mitochondria and need to be released out of mitochondria as critical signalling molecules for the rest of the cell. Finally, we will use fly models to investigate at a whole organism level the role of those quality control mechanisms that preserve protein redox homeostasis in the IMS on lifespan.
Our findings offer the first opportunity to explore a poorly characterised reductive pathway in mitochondria and its impact or redox homeostasis. This is critical to effectively defend cells against deleterious oxidative stress and sustain survival. The work is likely to provide a novel paradigm for understanding the coordination of protein redox control and oxidative stress signalling in eukaryotic cells and their effects on ageing.

Technical Summary

Our aim is to elucidate the redox protein quality control processes in mitochondria and how they impact the ageing process. This knowledge is missing and is a prerequisite to fully understand how mitochondria can maintain a healthy redox balance that is critical for cell survival and stress resistance. This requires a knowledge of both oxidative and reductive pathways and an interplay of these with mitochondrial ROS (mtROS) to preserve mitochondrial fitness in response to deleterious stresses and metabolic alterations. This is particularly important in maintaining the redox reactions within boundaries that are beneficial for cell physiology and survival across the lifespan rather than detrimental due to cell damage

We will use a combined biochemistry, cell biology and redox biology approach bringing together the expertise of the two applicants using three model systems ie yeast, mammalian cultured cells and Drosophila. Our work program will (1) investigate how reductive machinery operates in the IMS in retention of folded protein retention or retrograde export and degradation, (2) Dissect the effects on the global IMS redox state and mitochondrial metabolite transport in signalling processes and (3) Investigate the redox protein quality control as a key determinant in organismal ageing using Drosophila.
The proposed work will transform our knowledge by developing key aspects of mitochondrial biology shedding new light on how an IMS redox quality control operates in response to stresses and metabolic alterations to sustain mitochondrial homeostasis across the lifespan.

Publications

10 25 50
 
Description MItotargin as a diganostic tool for mitochondria - market research
Amount £5,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 03/2023 
End 05/2023
 
Title Fluorescence assay for monitoring peptide targeting into isolated mitochondria 
Description We have established a new method for monitoring uptake of targeting peptides to isolated mitochondria, using a fluorescently labelled synthetically made peptide. The assay is used to assess the capacity of a peptide to be targeted and internalised into the mitochondrial intermembrane space (IMS). It has been validated for peptides that follow distinct import routes into the IMS. Specificity has been tested using mitochondria devoid of key protein import components as controls. 
Type Of Material Technology assay or reagent 
Year Produced 2019 
Provided To Others? No  
Impact Could be used for testing the mitochondrial targeting capacity of any synthetic peptide (libraries) with a fluorescent moiety tagged to the peptide 
 
Title SNAP and HALO tagged cells for fluorescent probe detection of ROS with sub-mitochondrial resolution 
Description We have generated SNAP- and Halo tagged versions for cells expressing the tags in all submitochondrial locations. These can be used to label (using appropriate fluorescent ligand probes selective for SNAP or Halo proteins) in specific sub-compartments ROS species (hydogen peroxide and superoxide) 
Type Of Material Technology assay or reagent 
Year Produced 2021 
Provided To Others? No  
Impact too early for impact . Expected to generate impact after publication of technology 
 
Title peptide based technology for delivering payload to mammalian cells 
Description developed a platform technology for delivering payload (small molecules, peptides and small proteins) to mitochondria in mammalian cells as a way to modulate their function. Applications range from improving mitochondrial function in cases of primary mitochondria diseases and common conditions (neurodegeneration, diabetes) where mitochondria is an underpinning problem to blocking mitochondria function as a means of cell killing of cancer cells. 
Type Of Material Technology assay or reagent 
Year Produced 2020 
Provided To Others? No  
Impact IP rights generated - patent filed Initiated discussion with Venture capital companies interested in the technology New funding obtained (MRC Proximity to discovery award, BBSRC-EPSRC Impact accelerator award, Wellcome Trust Early stage discovery award) Market research outsourced to company and completed 
 
Description Mymito mission weekend 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact I was invited as an expert in the first weekend of the MyMItoMission patient organisaiton. I gave a talk on the importance of interdisciplinaty approach on mitochodnrial research and on the creation of a mitochondria research cluster in the University of Glasgow and the Mitochondria Collective, an intenrational netowk of mitohcondria research.
Year(s) Of Engagement Activity 2022
 
Description PDRA participated in the European Drosophila meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presented poster on the inolfuence of the mitochodnrial IMS redox system on ageing
Year(s) Of Engagement Activity 2023
 
Description Participation in a Royal Society of Chemistry meeting on ageing 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presentation of short talk
Year(s) Of Engagement Activity 2023
 
Description Patient group engagement 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact I led two focus group discussions in the Lily Foundation patient family weekend. The Lily Foundation is the largets UK patient organisation for patients suffering from mitochondria disease. THere was a brief presentation from me on 'Basic mito facts' and 'International collaboration on mitohcondrial research' that was followed by patient families (one group of 20 and one group of 15. I also engaged in panel discussions (audience of about 70-80 people)
Year(s) Of Engagement Activity 2022